Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury

Autor: Seyed H. Farzaneh, Shiri Li, Kelly Vo, M. Takasu, Christine Pham, Hirohito Ichii, Chie Takasu, Mitsuo Shimada, Michael J. Stamos, Nosratola D. Vaziri, Lourdes Robles
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Pathology
Dimethyl Fumarate
Apoptosis
medicine.disease_cause
Rats
Sprague-Dawley
chemistry.chemical_compound
0302 clinical medicine
Adenosine Triphosphate
Ischemia
Malondialdehyde
Dimethyl fumarate
biology
Liver Disease
Gastroenterology
NF-kappa B
Alanine Transaminase
General Medicine
Basic Study
Catalase
Liver
030220 oncology & carcinogenesis
Reperfusion Injury
Inflammation Mediators
medicine.medical_specialty
Nitric Oxide Synthase Type III
Glutamate-Cysteine Ligase
Clinical Sciences
Nitric Oxide
Nrf2
Nitric oxide
03 medical and health sciences
Internal medicine
medicine
Animals
Humans
Reactive oxidative stress
Peroxidase
Inflammation
Gastroenterology & Hepatology
business.industry
Animal
medicine.disease
Rats
CTL
Disease Models
Animal
Oxidative Stress
030104 developmental biology
Endocrinology
chemistry
Alanine transaminase
Cyclooxygenase 2
Disease Models
biology.protein
Liver function
Sprague-Dawley
business
Digestive Diseases
Reactive Oxygen Species
Reperfusion injury
Oxidative stress
Zdroj: World Journal of Gastroenterology
World journal of gastroenterology, vol 23, iss 25
Takasu, C; Vaziri, ND; Li, S; Robles, L; Vo, K; Takasu, M; et al.(2017). Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury. WORLD JOURNAL OF GASTROENTEROLOGY, 23(25), 4508-4516. doi: 10.3748/wjg.v23.i25.4508. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1cz2b6kv
ISSN: 2219-2840
1007-9327
Popis: AIM To investigate the hypothesis that treatment with dimethyl fumarate (DMF) may ameliorate liver ischemia/reperfusion injury (I/RI). METHODS Rats were divided into 3 groups: sham, control (CTL), and DMF. DMF (25 mg/kg, twice/d) was orally administered for 2 d before the procedure. The CTL and DMF rats were subjected to ischemia for 1 h and reperfusion for 2 h. The serum alanine aminotransferase (ALT) and malondialdehyde (MDA) levels, adenosine triphosphate (ATP), NO × metabolites, anti-oxidant enzyme expression level, anti-inflammatory effect, and anti-apoptotic effect were determined. RESULTS Histological tissue damage was significantly reduced in the DMF group (Suzuki scores: sham: 0 ± 0; CTL: 9.3 ± 0.5; DMF: 2.5 ± 1.2; sham vs CTL, P < 0.0001; CTL vs DMF, P < 0.0001). This effect was associated with significantly lower serum ALT (DMF 5026 ± 2305 U/L vs CTL 10592 ± 1152 U/L, P = 0.04) and MDA (DMF 18.2 ± 1.4 μmol/L vs CTL 26.0 ± 1.0 μmol/L, P = 0.0009). DMF effectively improved the ATP content (DMF 20.3 ± 0.4 nmol/mg vs CTL 18.3 ± 0.6 nmol/mg, P = 0.02), myeloperoxidase activity (DMF 7.8 ± 0.4 mU/mL vs CTL 6.0 ± 0.5 mU/mL, P = 0.01) and level of endothelial nitric oxide synthase expression (DMF 0.38 ± 0.05-fold vs 0.17 ± 0.06-fold, P = 0.02). The higher expression levels of anti-oxidant enzymes (catalase and glutamate-cysteine ligase modifier subunit and lower levels of key inflammatory mediators (nuclear factor-kappa B and cyclooxygenase-2 were confirmed in the DMF group. CONCLUSION DMF improved the liver function and the anti-oxidant and inflammation status following I/RI. Treatment with DMF could be a promising strategy in patients with liver I/RI.
Databáze: OpenAIRE
Externí odkaz: